[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602271":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":51,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"RADIATION","Stereotactic body radiotherapy (SBRT)","Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Nalee Kim, MD, PhD","CONTACT","82-2-3410-2612","nalee.kim@samsung.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":7,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Samsung medical center","RECRUITING","Seoul","06351","South Korea",{"type":27,"coordinates":28},"Point",[29,30],126.9784,37.566,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":17,"phoneExt":7,"email":18},"Nalee Kim",{"type":36,"investigatorFullName":34,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Assistant professor","100602271","smc-radiation-oncology-sabr-cohort-for-oligometastasis-100602271",false,"NCT07121335","SMC Radiation Oncology SABR Cohort for Oligometastasis","Cohort Study for Local Stereotactic Body Radiotherapy in Patients With Oligometastatic or Oligoprogressive Cancer","SABR-OMOP","Inclusion Criteria:\n\n* Performance status (ECOG PS) 0-2\n* Diagnosed with metastatic disease\n* Confirmed to have oligometastatic\u002Foligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)\n\nExclusion Criteria:\n\n* Patient with a history of prior radiotherapy to the site planned for SABR\n* Patients with concomitant brain metastases","ALL","18 Years",{"count":49,"type":50},60,"ESTIMATED","3 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.\n\nThe main questions it aims to answer are:\n\n1. oncologic outcomes (progression-free survival, local failure rate),\n2. patient-reported outcomes,\n3. physician-assessed toxicity, and\n4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.",[55,56,57,58,59],"Stereotactic Body Radiation Therapy (SBRT)","Oligometastasis","Oligoprogression","ctDNA","Patient-Reported Outcomes (PRO)",[61,56,57,58],"Stereotactic body radiotherapy","2025-08-08",{"date":64,"type":65},"2025-08-13","ACTUAL",{"date":67,"type":65},"2025-05-01",{"date":69,"type":50},"2030-03-31",{"name":5,"class":6},1]